CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 3.9% – Time to Sell?

CRISPR Therapeutics AG (NASDAQ:CRSP)’s share price fell 3.9% during mid-day trading on Tuesday . The stock traded as low as $40.82 and last traded at $41.63. 586,834 shares changed hands during trading, a decline of 74% from the average session volume of 2,241,707 shares. The stock had previously closed at $43.34.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a report on Thursday, February 13th. Bank of America lowered their price target on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Chardan Capital lowered their price target on shares of CRISPR Therapeutics from $94.00 to $84.00 and set a “buy” rating on the stock in a report on Thursday, February 13th. HC Wainwright restated a “buy” rating and issued a $65.00 price target on shares of CRISPR Therapeutics in a report on Thursday, February 13th. Finally, Needham & Company LLC restated a “buy” rating and issued a $84.00 price target on shares of CRISPR Therapeutics in a report on Wednesday, February 12th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat.com, CRISPR Therapeutics has an average rating of “Hold” and a consensus price target of $73.11.

CRISPR Therapeutics Stock Down 3.4 %

The stock has a fifty day moving average of $43.02 and a 200-day moving average of $45.65. The stock has a market capitalization of $3.60 billion, a price-to-earnings ratio of -9.61 and a beta of 1.77.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. On average, equities analysts forecast that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Insider Transactions at CRISPR Therapeutics

In other CRISPR Therapeutics news, Director John Greene acquired 7,000 shares of the business’s stock in a transaction on Wednesday, February 26th. The stock was purchased at an average price of $44.85 per share, for a total transaction of $313,950.00. Following the completion of the transaction, the director now owns 7,000 shares of the company’s stock, valued at $313,950. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Samarth Kulkarni sold 18,360 shares of the stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total value of $1,013,472.00. Following the completion of the transaction, the chief executive officer now owns 171,613 shares of the company’s stock, valued at $9,473,037.60. The trade was a 9.66 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 32,381 shares of company stock worth $1,608,243 over the last 90 days. 4.10% of the stock is currently owned by insiders.

Institutional Trading of CRISPR Therapeutics

Several large investors have recently bought and sold shares of CRSP. Wood Tarver Financial Group LLC acquired a new stake in shares of CRISPR Therapeutics during the fourth quarter valued at $30,000. Ameriflex Group Inc. acquired a new stake in shares of CRISPR Therapeutics during the fourth quarter valued at $36,000. Highline Wealth Partners LLC acquired a new stake in shares of CRISPR Therapeutics during the fourth quarter valued at $39,000. Western Pacific Wealth Management LP boosted its stake in shares of CRISPR Therapeutics by 100.0% during the fourth quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock valued at $39,000 after acquiring an additional 500 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new stake in shares of CRISPR Therapeutics during the third quarter valued at $40,000. Institutional investors and hedge funds own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.